#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Internal Medicine - Issue 11/2014

Reviews

926
New SGLT2 inhibitor empagliflozin: modern and safe treatment of diabetes

Zdeněk Rušavý

931
Prevention of cardiovascular diseases in clinical practice: is it possible to achieve improvement?

Tomáš Štulc, Michaela Šnejdrlová, Richard Češka

937
Residual cardiovascular risk markers

Hana Rosolová, Barbora Nussbaumerová

942
New aspects of hormone replacement therapy

Tomáš Fait

949
News in lipid lowering treatment

Michal Vrablík, Richard Češka

958
Non-pharmacological treatment – results from Poděbrady

Lukáš Zlatohlávek, Michal Vrablík, Zuzana Urbanová, Hana Pejšová, Jaroslav Hubáček, Richard, Češka

963
Familial hypercholesterolemia – past and present.
My experiences and findings in our group of patients with familial hypercholesterolemia

Richard Češka, Michal Vrablík, Tereza Altschmiedová, Martina Prusíková, Zuzana Urbanová, Josef Šobra

970
LDL-apheresis in the treatment familial hypercholesterolemia

Vladimír Bláha, Milan Bláha, Miriam Lánská, Eduard Havel, Pavel Vyroubal, Zdeněk Zadák, Pavel Žák, Luboš Sobotka

977
Extended options of anticoagulant treatment in thromboembolism

Debora Karetová, Jan Bultas

985
What do have arterial and venous disease in common?

Jan Piťha, Ondřej Auzký, Karel Roztočil

991
Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey

Michal Vrablík, Zdeněk Chmelík, Věra Lánská


Actualities

999
Adherence of type 2 diabetes patients on insulin analogues application: missed dose, time imprecision and dose reduction
The results of GAPP2TM(Global Attitudes of Physicians and Patient) survey in the Czech Republic

Martin Prázný


Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#